Joel Rovnak , Randall J Cohrs
Translational medicine and virology are intimate partner on the road towardsÂ effective personal healthcare. A driving force for the development of more efficientÂ high-throughput screening technologies is the search for more effective antivirusÂ therapies. Perhaps the most promising â€˜golden fleeceâ€™ of translational research isÂ individual designer medicines synthesized from the patientâ€™s own cells which haveÂ been removed and genetically altered before replacement. This technology has itsÂ beginnings in virology where gene transfer is easily accomplished and its ultimateÂ success will be through advances in the field of virology where promoter modificationsÂ will drive the synthesis of specific proteins in both a time and cell dependent manner.Â With this in mind, it would benefit those interested in translational medicine to keepÂ abreast of current topics in virology.Â The 11thÂ annual meeting of the Rocky Mountain Virology Association (RMVA) wasÂ held Sept. 23-25, 2011 at the forestry extension campus of Colorado State UniversityÂ (Pingree Park). RMVA (www.RockyMountainVirologyClub.org) began in 2001 as aÂ regional gathering of virologists to share and discuss scientific data and ideas, andÂ to provide a venue for graduate students to present their findings in a relaxed butÂ professional setting. Since its inception, RMVA has attracted virologist from the RockyÂ Mountain area along with nationally and internationally recognized scientists, andÂ has fostered interdisciplinary collaborations, assisted in grant development and hasÂ been the sounding board for multiple manuscripts. Autumn was selected to have theÂ annual RMVA meeting coincide with the peak Aspen color change, and this year wasÂ not a disappointment. Herein a brief summary by the contributing author (identifiedÂ by number in the figure) is presented.